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Poster Session II S299p5 0.035) and higher overall survival (HR: 0.60, 95%CI: 0.36-0.99,
p5 0.047) than those who received stem cells from a donor without
the C-A-A haplotype. Additionally, the group with the
C-A-A haplotype exhibited high disease-free survival (HR: 0.66,
95%CI: 0.41-1.06, p5 0.085), compared with the group without
the haplotype C-A-A. The presence or absence of the C-A-A haplo-
type did not affect the incidence of acute and chronic GVHD, and
non-relapse mortality. This is the first report described the effect
of CTLA-4 haplotype, but not each SNP, on allogeneic HSCT.
Since the presence of CTLA-4 haplotype C-A-A reduced the risk
of relapse and improved survival after allogeneic HSCT, CTLA-4
haplotype may provide useful information for donor selection.Blockade of two independent innate immunity pathways syn-
ergistically prevent lethal graft-versus-host disease
Groups n
Survival at
day 150
Survival at
day 1100
TCD BM alone 10 100% 100%
Wildtype 1 isotype 10 20% 10%
Wildtype 1 anti-C5 10 40% 30%
MyD88-/- 1 isotype 10 50% 20%
MyD88-/- 1 anti-C5 10 90% 80%
P\0.01, MyD88-/-1 anti-C5 vs. other groups. A representative exper-
iment of three is shown.383
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Allogeneic bone marrow transplantation (BMT) represents the
most effective treatment for patients with high risk and relapsed
hematologic malignancies because allogeneic donor T cells pro-
vide a graft-versus-leukemia (GvL) effect. However, the same cells
can cause graft-versus-host disease (GvHD), one of the major
complications. Regulatory T cells (Tregs) have been shown to
suppress GvHD while preserving GvL, their use provides a prom-
ising strategy in the allogeneic transplant setting if three major
obstacles will be overcome: 1) the low numbers of Tregs, 2)
loss of suppressor activity following ex vivo expansion and 3) the
lack of Treg-specific markers to purify ex vivo expanded Tregs.
The FOXP3 transcription factor, which is exclusively expressed
in Tregs, can convert effector T cells (Teff) into Tregs when ec-
topically overexpressed. The Foxp3 locus is unmethylated in Tregs
while highly methylated and silenced in all other T cells. The hy-
pomethylating agent azacitidine (AzaC) can modulate this methyl-
ation status and induce stable FOXP3 expression (.7 days) in
Teff. Furthermore, we have shown that these AzaC-induced
FOXP3 +T cells are suppressive phenotype in vitro. Thus, we hy-
pothesize that AzaC treatment of mice after allogeneic BMT will
dramatically mitigate GvHD while preserving GvL via upregula-
tion of Foxp3 in alloreactive Teff.
In murine T cell depleted (TCD) BMT model (B6/ Balb/c)
with delayed infusion of conventional T cells (Tconv) (2X106) at
day 11 post BMT, followed by subcutaneous treatment of AzaC
(2 mg/kg at days 15, 17, 19, and 21 post BMT), we found that
AzaC dramatically suppressed GvHD caused by allogeneic donor
T cells while maintaining donor engraftment of all lineages. The
AzaC group had significantly higher FOXP3 +Tregs than in PBS
control group and that these Tregs were derived from donor T
cells, suggesting that the suppression of GvHD was mediated by
AzaC-induced Tregs. We further tested whether AzaC treatment
of mice transplanted with allogeneic T cells preserve GvL while
mitigating GvHD. Using the same murine allogeneic BMT
model, Click Beetle Red luciferase-expressing A20 leukemia cells
(Balb/c derived; 1X104) were injected with TCD BM and
10106 Tconv and in vivo bioluminescence imaging was per-
formed to assess tumor burden. We found that AzaC treatment
mitigated GvHD without abrogating GvL or donor engraftment.
Thus, the adminstration of hypomethylating agents like AzaC
might be a promising strategy to treat GvHD.384
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Graft-versus-host disease (GVHD) is a major complication fol-
lowing hematopoietic cell transplantation. Innate immunity plays
a major role in the development of GVHD both by aiding allogeneic
T cell responses and by damaging target organs directly. MyD88 is
an adaptor protein for the majority of toll-like receptors. The com-plement system is a central component of the innate immune
response. We studied the role of these two pathways in the develop-
ment of GVHD using the C57BL/6 into BALB/c model. Lethally
irradiated recipients of MyD88-/- T cells survived slightly longer
than recipients of wild type cells (median survival time: 48 vs. 32
days, P\0.05). Similarly, treatment with an anti-C5 antibody (clone
BB5.1, 1 mg/dose, i.p., three times a week for 4 weeks), that blocks all
three pathways of complement activation and prevents cell lysis, also
moderately prolonged the survival of the mice with GVHD com-
pared with the isotype control group (median survival time: 43 vs.
32 days). Treatment of MyD88-/- T cell recipients with anti-C5 an-
tibody protected 80% of the animals from lethal GVHD at 100 days
post transplantation, while only 20% in the MyD88-/- T cell recipi-
ents treated with isotype antibody group and 30% in the wildtype T
cell recipients treated with anti-C5 antibody group survived (Table,
P\0.01, compared with other groups). All MyD88-/- T cell recipi-
ents treated with anti-C5 antibody developed GVHD.However, the
disease was less severe in these animals than those in the recipients of
a single pathway blockade as measured by body weight and other
clinical signs of GVHD. The anti-C5 antibody did not seem to pre-
vent GVHD through inhibiting T cell activation and expansion
because it did not inhibit mixed lymphocyte reactions. Levels of mul-
tiple pro-inflammatory cytokines were lower in the MyD88-/- T cell
recipients treated with anti-C5 antibody compared with those in the
control groups. These data clearly demonstrate that, even though
blockade of MyD88 or complement pathway alone may prevent
GVHD, GVHD can be better controlled by blocking both
MyD88 and complement pathways.385
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Mycophenolate mofetil (MMF) is a common and effective pro-
phylactic immune suppressant that promotes hematopoietic cell en-
graftment and prevents graft vs host disease (GVHD) after
allogeneic hematopoietic stem cell transplant (HCT). However,
there is limited data as to the effectiveness of MMF plus high dose
corticosteroids for the treatment of acute GVHD and even less
data regarding the pharmacokinetic disposition and exposure-re-
sponse relationship of mycophenolate in individuals with GVHD.
Mycophenolate pharmacokinetics were studied in a multi-center
CTN randomized phase II trial evaluating the effectiveness of
MMFas one if four novel agents added to steroids as initial treatment
of acute GVHD. Thirty-two patients randomized to receiveMMF 1
gm twice daily who underwent pharmacokinetic sampling in weeks 1
and 2 were studied. Median age was 416 13.6 years. Twenty one
(65.6%), 5 (15.6%), 6 (18.8%) patients had a complete response
(CR), partial response (PR) or lesser response by day 28, respectively.
